Importance Cardiovascular adverse events (CVAE) with carfilzomib in patients with multiple
myeloma can be potentially life-threatening and remain incompletely characterized. We …

Proteasome inhibitors (PIs) are the backbone of combination treatments for patients with
multiple myeloma and AL amyloidosis, while also indicated in Waldenström's …

Carfilzomib (Cfz), an irreversible proteasome inhibitor licensed for relapsed/refractory
myeloma, is associated with cardiotoxicity in humans. We sought to establish the optimal …

Abstract Purpose of Review Multiple myeloma is the second most common hematologic
malignancy in the USA, with over 32,000 new cases and nearly 13,000 deaths expected in …

As medicine advances to employ sophisticated anticancer agents to treat a vast array of
oncological conditions, it is worth considering side effects associated with several …

Oncology has seen growing use of newly developed targeted therapies. Although this has
resulted in dramatic improvements in progression-free and overall survival, challenges in …

The treatment for multiple myeloma has advanced significantly over the past few decades.
Proteasome inhibitors have become the cornerstone of the treatment of multiple myeloma …

Among the different mechanisms involved in oxidative stress, protein carbonylation and lipid
peroxidation are both important modifications associated with the pathogenesis of several …

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that causes irritation,
inflammation, and ulceration in the linings of the colon and rectum. Otostegia fruticosa is …

The use of proteasome inhibitors (PI) as targeted chemotherapeutics have significantly
improved survival in patients with multiple myeloma (MM). However, rare and serious …